MoonLake FY 2023 net loss $44.1M; cash $511M; sonelokimab Phase 3 prep advances

MoonLake Immunotherapeutics

2023-FY EPS reported -$0.73

Cash, cash equivalents and short-term marketable debt securities $511.0M at Dec 31, 2023, up from $496M at Sep 30, 2023.
Net loss for FY 2023 $44.1M, improved from $64.5M in FY 2022.
R&D expenses $31.8M in FY 2023, down from $42.0M in FY 2022.
Completed positive Phase 2 data for sonelokimab in HS and PsA; FDA/EMA feedback supports Phase 3 VELA program in HS.
Raised $85M gross proceeds from at-the-market offerings; cash runway expected to end of 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

MoonLake Immunotherapeutics reported the quarter and fiscal year ended December 31, 2023 results: net income $44.1 million.

Period: the quarter and fiscal year ended December 31, 2023
Net income: $44.1 million
Result: reported results

Exact text from the filing

MoonLake Immunotherapeutics (the “Company”) issued a press release announcing its financial results for the quarter and fiscal year ended December 31, 2023.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

MoonLake Immunotherapeutics filing history →

Source: SEC EDGAR

accession 0001821586-24-000007

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.